Table 3.

SIRs of patients stratified by histology findings

Histology record − broad groups	Observed	Expected	O/E	95% CI
8140–8389: adenomas and adenocarcinomas	2536	2,427.74	1.04#	1–1.09
8500–8549: ductal and lobular neoplasms	713	810.21	0.88#	0.82–0.95
8720–8799: nevi and melanomas	593	451.13	1.31#	1.21–1.42
8120–8139: transitional cell papillomas and carcinomas	255	268.81	0.95	0.84–1.07
8050–8089: squamous cell neoplasms	197	280.69	0.7#	0.61–0.81
9670–9699: nhl − mature b-cell lymphomas	173	148.55	1.16	1–1.35
9820–9839: lymphoid leukemias (C42.1)	101	72.32	1.4#	1.14–1.7
8440–8499: cystic, mucinous, and serous neoplasms	96	101.45	0.95	0.77–1.16
8010–8049: epithelial neoplasms, NOS	78	87.71	0.89	0.7–1.11
9730–9739: plasma cell tumors	56	44.24	1.27	0.96–1.64
9950–9969: chronic myeloproliferative disorders (C42.1)	49	32.54	1.51#	1.11–1.99
8000–8009: unspecified neoplasms	29	24.63	1.18	0.79–1.69
9590–9599: malignant lymphomas, NOS or diffuse	29	21.05	1.38	0.92–1.98
9980–9989: myelodysplastic syndrome	29	27.69	1.05	0.7–1.5
8550–8559: acinar cell neoplasms	25	23.46	1.07	0.69–1.57

CI, confidence interval.

^#Means p < 0.05.